Cencora, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a COR research report →
Companywww.cencora.com
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.
- CEO
- Robert Mauch
- IPO
- 1995
- Employees
- 47,000
- HQ
- Conshohocken, PA, US
Price Chart
Valuation
- Market Cap
- $51.51B
- P/E
- 20.21
- P/S
- 0.16
- P/B
- 15.16
- EV/EBITDA
- 15.04
- Div Yield
- 0.89%
Profitability
- Gross Margin
- 3.47%
- Op Margin
- 1.28%
- Net Margin
- 0.78%
- ROE
- 115.93%
- ROIC
- 11.89%
Growth & Income
- Revenue
- $321.33B · 9.31%
- Net Income
- $1.55B · 2.99%
- EPS
- $8.02 · 5.53%
- Op Income
- $3.65B
- FCF YoY
- 6.99%
Performance & Tape
- 52W High
- $377.54
- 52W Low
- $244.82
- 50D MA
- $309.34
- 200D MA
- $326.81
- Beta
- 0.65
- Avg Volume
- 1.68M
Get TickerSpark's AI analysis on COR
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 1, 26 | Tyler Lauren M | other | 99 |
| May 1, 26 | Cooper Ellen | other | 99 |
| May 1, 26 | NALLY DENNIS M | other | 116 |
| Apr 1, 26 | Krikorian Lazarus | other | 3,936 |
| Mar 11, 26 | Battaglia Silvana | other | 8,415 |
| Mar 11, 26 | Battaglia Silvana | other | 3,673 |
| Mar 11, 26 | Battaglia Silvana | other | 8,415 |
| Mar 11, 26 | Campbell Elizabeth S | other | 12,623 |
| Mar 11, 26 | Campbell Elizabeth S | other | 5,842 |
| Mar 11, 26 | Campbell Elizabeth S | other | 12,623 |
Our COR Coverage
View all →
Cencora, Inc. (COR) slumps on Q2 miss: deep earnings analysis
Cencora, Inc. (COR) slumps after missing on EPS and revenue, but the full story goes beyond the headline. This deep-dive unpacks U.S. Healthcare Solutions pressure, international strength, margin shifts, and why raised EPS guidance couldn’t offset a revenue reset.
Cencora, Inc. (COR) slumps 17% after mixed Q2
Cencora, Inc. (COR) slumps after a mixed fiscal Q2 2026 report. Revenue rose and full-year guidance increased, but adjusted EPS missed expectations, sparking heavy selling as investors reassess the stock’s premium valuation and execution outlook.
Cencora (COR): Specialty Growth Is Driving Earnings
Cencora is using specialty expansion and GLP-1 volume to grow earnings faster than revenue. The stock looks constructive for medium-term investors, with solid guidance and a reasonable forward valuation.
Want a deeper read on COR?
Generate a full analyst-grade report — bull / bear case, price targets, valuation depth, and a complete financial breakdown.